A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease. (NCT07753993)
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants With Chronic Kidney Disease (Elevate-CKD)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Who can join: Review the eligibility criteria below.
Location: Research Site — Sheffield, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (426 Sites)
Showing the first 25 of 426 sites.
- Research Site — Sheffield, Alabama
- Research Site — Surprise, Arizona
- Research Site — Chula Vista, California
- Research Site — Waterbury, Connecticut
- Research Site — Chicago, Illinois
- Research Site — Topeka, Kansas
- Research Site — Beltsville, Maryland
- Research Site — Boston, Massachusetts
- Research Site — Troy, Michigan
- Research Site — Edina, Minnesota
- Research Site — Saint Paul, Minnesota
- Research Site — Eatontown, New Jersey
- Research Site — Albany, New York
- Research Site — Buffalo, New York
- Research Site — Mineola, New York
- Research Site — Morehead City, North Carolina
- Research Site — Shelby, North Carolina
- Research Site — Statesville, North Carolina
- Research Site — Wilmington, North Carolina
- Research Site — Wilmington, North Carolina
- Research Site — Maumee, Ohio
- Research Site — Rapid City, South Dakota
- Research Site — Knoxville, Tennessee
- Research Site — Morristown, Tennessee
- Research Site — Arlington, Texas
📞 Contact the Study Coordinator
Phone: (877) 240-9479
Email: information.center@astrazeneca.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Kidney Disease
- Trial to Evaluate and Assess the Effect of Comprehensive Pre-ESKD Education on Home Dialysis Use in Veterans — Gainesville, Florida
- A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting — Huntsville, Alabama
- Nitrite-boosting Therapy for Improving Physiological Function in Patients With Chronic Kidney Disease — Boulder, Colorado
- "Residual Kidney Function and Oxidative Stress in Incremental vs Standard Peritoneal Dialysis (2 Mexican Centers)" — León, Guanajuato
- Dine and DASH Into Wellness Pilot Study — Durham, North Carolina
- An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States — Whippany, New Jersey
Explore by condition: All Chronic Kidney Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.